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Abstract
Background: In contrast to studies of depression and psychosis, the first part of this study showed no major 
differences in serum levels of cytokines and tryptophan metabolites between healthy children and those with 
attention-deficit/hyperactivity disorder of the combined type (ADHD). Yet, small decreases of potentially toxic 
kynurenine metabolites and increases of cytokines were evident in subgroups. Therefore we examined predictions of 
biochemical associations with the major symptom clusters, measures of attention and response variability.
Methods: We explored systematically associations of 8 cytokines (indicators of pro/anti-inflammatory function) and 5 
tryptophan metabolites with symptom ratings (e.g. anxiety, opposition, inattention) and continuous performance test 
(CPT) measures (e.g. movement, response time (RT), variability) in 35 ADHD (14 on medication) and 21 control children. 
Predictions from linear regressions (controlled by the false discovery rate) confirmed or disconfirmed partial 
correlations accounting for age, body mass and socio-economic status.
Results: (1) Total symptom ratings were associated with increases of the interleukins IL-16 and IL-13, where relations of 
IL-16 (along with decreased S100B) with hyperactivity, and IL-13 with inattention were notable. Opposition ratings 
were predicted by increased IL-2 in ADHD and IL-6 in control children. (2) In the CPT, IL-16 related to motor measures 
and errors of commission, while IL-13 was associated with errors of omission. Increased RT variability related to lower 
TNF-α, but to higher IFN-γ levels. (3) Tryptophan metabolites were not significantly related to symptoms. But increased 
tryptophan predicted errors of omission, its breakdown predicted errors of commission and kynurenine levels related 
to faster RTs.
Conclusions: Many associations were found across diagnostic groups even though they were more marked in one 
group. This confirms the quantitative trait nature of these features. Conceptually the relationships of the pro- and 
antiinflammatory cytokines distinguished between behaviours associated more with cognitive or more with motor 
control respectively. Further study should extend the number of immunological and metabolic markers to confirm or 
refute the trends reported here and examine their stability from childhood to adolescence in a longitudinal design.
Background
Essential components of the diagnosis of attention-defi-
cit/hyperactivity disorder of the combined type (ADHD)
are clinical impairments of attention, impulsivity and
hyperactivity.
Further, the variability of the expression of these symp-
toms and of neuropsychological measures in the labora-
tory is viewed as central to the syndrome and has been
proposed as an endophenotype of the disorder [1-4].
Neuronal firing must be maintained to sustain a behav-
ioural response. A recent hypothesis [5] proposed that an
inefficient supply of energy from glial cells (the lactate
shuttle: [6]) might underlie the intra-individual variability
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in behaviour and the underlying neuronal activity of chil-
dren with ADHD.
The cytokine and growth factor S100B is a potential
marker of glial function. Serum levels arise largely but not
exclusively from astrocytes [7]. Increases have been asso-
ciated with brain damage, major depression, psychosis
and dementia [8-10]. However, our pilot study of children
with ADHD found that levels of S100B were not unusual,
although a tendency for levels to decrease in those with
internalizing symptoms was noted [11].
Tryptophan metabolism along the kynurenine pathway
takes place primarily in glia [12]. Our study [11] also
recorded levels of these metabolites and some cytokines
that influence the metabolism [13] as further potential
indicators of glial integrity. Relevant to our hypothesis on
glial function is that metabolites of kynurenine can be
neuroprotective (e.g. kynurenate) or potentially toxic (3-
hydroxy-kynurenine, 3-HK) and that the balance between
these metabolic routes is modulated by the relative activ-
ity of the pro- and anti-inflammatory cytokines [13].
Our initial analysis [11] reported a modest imbalance of
cytokines in children with ADHD (figure 1). This
improved in those treated with methylphenidate, and
thus arguably reflected an increased allostatic load [14].
In the kynurenine pathway, we noted lower levels of the
potentially toxic 3HK in children with ADHD than con-
trols that could reflect a maturational delay [15] of the
neuronal pruning processes seen in typically developing
children [16,17]. [However, an alternative metabolic route
for kynurenine over nicotine adenine dinucleotide
(NAD(+)) rather than the toxic quinolinic acid cannot be
excluded [18].]
As we had evidence for differences of the cytokine lev-
els and their associations specific to sub-groups (see
internalizing symptoms and S100B above, and interleukin
IL-10 and IL-16 in those with experience of allergy), we
proposed that there would be associations with the major
symptom clusters and underlying processes. In particular,
we focused on ratings of inattention, hyperactivity, oppo-
sition and anxiety, and laboratory measures of attention
where the coefficient of variation as a measure of variabil-
ity could be calculated. This aim has aetiological signifi-
cance firstly as the inattentive symptoms are those most
likely to persist into adulthood [19], and secondly the
measure of variability relates directly to the glial hypothe-
sis for the generation of features of ADHD [5]. On the
basis of allostasis we predicted that poorer measures of
attention would relate to increased levels of some cytok-
ines and reflect an imbalance between pro-and anti-
inflammatory activity.
The absence of previous work in this field makes pre-
cise predictions impractical. We know of only one study
of cytokines in ADHD [20] and one relating to kynure-
nine [21]. The former found no extreme values for type-1
or type-2 interleukins among patients with ADHD, unlike
those with schizophrenia or obsessive-compulsive disor-
der. The latter described a potential increase of kynure-
nine metabolism (over that for serotonin, 5-HT) in
ADHD following stimulant medication. Indeed, there is
substantial indirect evidence for considering a role for 5-
HT in ADHD, and by implication the availability of its
precursor tryptophan [22,23]. Thus, in the domain of
impulsivity, there is evidence for the genetic control in
ADHD of the expression of 5-HT receptors, its synthesis
and availability [24]. In the domain of sustained attention,
task performance related negatively to 5-HT metabolism,
and increased 5-HT metabolism (vs. dopamine metabo-
lism) was inversely related with the signal detection mea-
sure, d-prime [25]. In support of a continued
consideration of 5-HT metabolism here, we reported
moderately increased tryptophan availability in untreated
ADHD children [11].
Thus, this study represents an exploration of the
hypothesis that there are potentially functional associa-
tions of symptom ratings (e.g. inattention) and continu-
ous performance task measures (CPT: sustained
attention, impulsivity and variability) with 8 cytokines,
tryptophan and 4 tryptophan metabolites. The cytokines
include the interleukins IL-2, IL-6, interferon-gamma
(IFN-γ), tumour necrosis factor-alpha (TNF-α), IL-16, Il-
10, IL-13 and S100B. The metabolites include 5-hydroxy-
indoleacetic acid (5-HIAA), kynurenine, kynurenate, and
3HK.
Methods
Subjects
Twenty one medication-naïve, consecutively referred
children were diagnosed with ADHD combined type
(DSM-IV) and recruited to the ADHD-group. Fourteen
older children had been given the same diagnosis 4 years
earlier and were receiving medication (ADHDmed-
group). Their 7 healthy siblings [11] are not further con-
sidered here. Controls for the ADHD-group were 21 nor-
mally developing children recruited by advertisement.
For all groups exclusion criteria included a history of
encephalitis, autism, epilepsy, Tourette syndrome, bipolar
disorder, IQ ≤ 80, brain damage and any genetic or medi-
cal condition associated with externalizing behaviours
that might mimic ADHD. The protocol, respecting the
Declaration of Helsinki, was approved by the ethics com-
mittee of the medical faculty of the University of Duis-
burg-Essen. Verbal and written information on the study
was given to the children and the parents or guardians
who gave written consent to the procedures.
Diagnosis was based on a semi-structured interview of
the parents (Parental Account of Children's Symptoms,
PACS: [26,27]) on mood disorders, ADHD/hyperkinetic
syndrome, disruptive behaviour and additional problemsOades et al. Behavioral and Brain Functions 2010, 6:32
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of the children in structured and unstructured situations.
Following training with written definitions of the behav-
iours replies were rated for the previous week and year (in
a period without medication) on a 4-point scale. A stan-
dardized diagnostic algorithm based on the DSM-IV cri-
teria for the symptoms, age of onset, situational
pervasiveness and clinical impairment was applied to this
information. This procedure has achieved good inter-
rater reliability: (r = .76 to .96; [27]). Symptoms were
rated with the Conners parent and teacher ratings scales
(CPRS-R:L, CTRS-R:L: [28]). Internalizing and external-
izing symptoms were recognized on the anxiety and
oppositional subscales with T>65 on either the CTRS or
CPRS (9/14 [ADHD], 6/2 [controls], and 6/9 [ADH-
Dmed].
Information on gender, age, body-mass index (BMI),
IQ, socio-economic index (SES) and reported allergic
sensitivities is given in table 1. The IQ was assessed with
the CFT-20-R [29] or for children less than 9 years with
the Kaufman assessment battery [30]. The current and at-
birth reported SES of the father and mother for profes-
sion/qualification was scored on a scale of 1-7 [31]. Aller-
gies in the past (> 12 months) and currently experienced
were rated for severity (0-3).
Continuous performance test (CPT/Qb)
The CPT/Qb test provides data on sustained attention:
accuracy, response times and their variability and restless
movements [32]. It lasts 4-15 minutes depending on the
speed of response. A grey circle (target), and another with
a cross (nontarget) are presented in a random sequence
for 100 ms every 2 sec on a computer monitor. Half of the
450 stimuli require a button-press within 2 sec. Accuracy
is measured by the percentage errors of omission (sus-
tained attention) and commission (impulsivity). Multiple
and anticipatory responses (< 150 ms) were excluded
from the analysis. Response latency measures include the
mean reaction time (RT) the variation (standard devia-
tion, SD) and coefficient of variance (intra-individual
variability, CV = 100 × RT-SD/RT). During the task the
Figure 1 Shows serum levels (z-values) in 4 groups of subjects for 8 cytokines (the interleukins -1β, -2, -6, -16, TNF-α, IFN-γ, -10, -13).  Both 
control groups tended to have lower IFN-γ levels than the ADHD groups, and the ADHDmed group more IL-1β than the group with ADHD alone. * p 
= 0.03, # p = 0.1, ## p = 0.07.Oades et al. Behavioral and Brain Functions 2010, 6:32
http://www.behavioralandbrainfunctions.com/content/6/1/32
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Table 1: Characteristics of the ADHD, control and ADHDmed groups of children (means and standard deviations)
ADHD Control ADHDmed
mean SD mean SD mean SD
N 21 21 14
Gender (m/f) 14m, 7f 20 m, 1 f 12 m, 2 f
Age (y) 8.9** 1.4 11.0** 1.5 12.6 2.1
IQ 95.8* 10.7 114.1 14.4 106.7 12.4
Height (cm) 132.1 9.3 147.3 11.6 161.2 17.8
Weight (kg) 29.2 8.4 39.7 11.7 54.7 19.1
BMI 16.5*** 2.4 17.9*** 3.1 20.5 4.6
Allergy (N) 81 1 2
Allergy (grade) 0.95 1.2 0.76 0.9 0.29 0.7
SES-birth (M) 4.2 1.6 3.6 0.8 3.7 1.4
(F) 4.3 1.6 3.3 2 3.7 1.6
SES-current (M) 4.3 2.3 3.3 1.5 4.4 2
(F) 4.3 2.2 3.5 2.1 4.1 1.9
BMI = Body mass index,
SES = socio-economic scale for the mother (M) and father (F) at child birth and currently (scale 1-7)
Allergy = the number of subjects reporting allergic sensitivity and the rated severity (scale 0-3)
* p < 0.05 ** p < 0.02 *** p < 0.005Oades et al. Behavioral and Brain Functions 2010, 6:32
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subject's movements are recorded by an infrared camera
following a reflective marker on a headband. The camera
reads the X/Y coordinates of the marker, sampling 50x/
sec and scales (1/27) the measures to mm/sec. The dura-
tion of restlessness (time spent active [> 1 cm/sec] as a
percentage of task duration) and the number of microev-
ents (movements of >1 mm) are recorded [33].
Biochemistry
Details are given in the accompanying report [11]. Briefly,
fasting venous blood (20 ml) was drawn (08:00-09:00
a.m.), the serum separated and stored at -80°C for analy-
sis blind to the origin of the sample [13]. S100B was mea-
sured by an immuno-luminometric assay (detection limit
0.02 μg/L: ELECSYS S100™, Roche Diagnostics, Switzer-
land). The cytokines IL-1β, IL-2, IL-6, IL-10, IL-13, IL-16,
IFN-γ and TNF-α were analysed with ELISA test kits
from R&D systems. For IL-1β, IL-6, IL-10 and TNF-α
high-sensitive assays were used. IL-1β was not detected
in 40/63 samples (detection limit: 0.063 pg/ml) and
excluded from the correlational analysis.
For amino acid determination the AccQ Tag HPLC
method was used (Waters, Milford, MA, USA) and con-
cerned the 5 tryptophan-competing amino acids and 12
others [11]. The fluorescence wave lengths were λex =
250 nm and λem = 395 nm. Analyses for tryptophan and
the metabolites were run on a Waters 2695 chromato-
graph with a 2487 dual-l UV detector and a 2475 fluores-
cence detector. Tryptophan (lex: 300 nm; lem: 350 nm)
and 5-HIAA (lex: 300 nm; lem: 340 nm) were measured
with fluorescence, kynurenine (365 nm), kynurenate (330
nm) and 3-HK (365 nm) with UV detection. Three indi-
ces of metabolic activity were calculated: (1) Tryptophan
availability  [100 × tryptophan/sum of the competing
amino acids], (2) Tryptophan breakdown [kynurenine/
tryptophan] reflecting the summed metabolic enzymatic
activity, and (3a) the neuroprotective index [kynurenate/
3HK]. Neuroprotection would be increased with larger
values. The third index differs from Myint et al. [13] who
used the ratio of 1000 × kynurenate/kynurenine (index
3b) representing turnover within the protective pathway
rather than the production of toxic metabolites.
Data analysis
First, group comparisons (MANOVA) were performed for
group characteristics (table 1), symptom ratings and CPT
measures, and confirmed with Tukey tests. Symptom
subscales for opposition, anxiety, and the DSM scales for
inattention, hyperactive-impulsivity and sum scores were
analysed on the parent and the teacher scales (table 2).
Six CPT responses were selected as representative of
motor activity (duration, microevents), attention (errors
of omission and commission) and variability (coefficient
of variance and RT: table 3). Covariates for gender, age,
BMI, SES and IQ were considered and are reported where
relevant. Relevance was determined from predictions of
group characteristics by the biochemical measures in a
backwards step-wise regression. The first results' section
summarises these analyses.
The second results section reports the associations
sought between the group features and the functional
domains of attention and symptoms with the 3 sets of
biochemical measures (cytokines, tryptophan metabo-
lism and metabolic indices). Initially in this exploration
partial correlations were calculated accounting for the
relevant covariates (see above) for each group. Second
these results were confirmed/disconfirmed with linear
regression analysis to test the hypotheses that the bio-
chemical measures predict the symptoms and attentional
features. This assists in the elimination of false positives
in the correlational analysis. Applying the false discovery
rate to the results of the multiple regressions identifies
uncorrected probabilities reported as ≤ 0.01 as satisfying
α = 5%: values above this threshold are described as
trends or tendencies (p < 0.05/α < 10%). Following each
analytical section there is a short summary of the con-
firmed effects. For tryptophan metabolism measures of
tryptophan, kynurenine, kynurenate, 3HK and 5-HIAA
and separately the metabolic indices (above) were consid-
ered. For the cytokine associations analyses of S100B, IL-
2, IL-6, IL-16, TNF-α, IFN-γ, IL-10 and IL-13 measures
were considered. A few missing values were replaced by
the mean.
Results
(1) Group comparisons
Group features and comparisons of their symptoms and 
attentive behaviour
The three groups did not differ on gender distribution,
socio-economic scale or incidence of allergy (table 1).
ADHD children were younger than the controls and both
were younger than the ADHDmed group (p < 0.02): they
also had a lower BMI than the ADHDmed group (p <
0.005) and their IQ was lower than in either the ADH-
Dmed or control groups (p < 0.05).
Covarying for age and IQ, the CPRS symptom ratings
were clearly higher for both ADHD groups than the con-
trols on each scale except anxiety. The anxiety ratings
were only a little higher in the ADHD groups than in con-
trols. Similar but less marked differences were shown
with the CTRS. There were no differences between the
ADHD groups (table 2). Using the same covariates atten-
uated the group differences on CPT measures, but only
that for the errors of commission errors lost significance.
Compared to the ADHD groups controls showed less
motor activity, a shorter RT with less variability and more
errors of omission (table 3). While post-hoc comparisons
of the two ADHD groups showed that medication did notOades et al. Behavioral and Brain Functions 2010, 6:32
http://www.behavioralandbrainfunctions.com/content/6/1/32
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significantly reduce RT or errors of omission, the ADH-
Dmed group did show fewer microevents, a shorter dura-
tion of activity, less RT variability and fewer errors of
commission.
Group comparisons: tryptophan metabolism and cytokines
Tryptophan levels and availability were modestly higher
and breakdown indices lower in those with a diagnosis of
ADHD after controlling for age and gender (figure 2,
[11]). But this was not reflected in altered levels of 5-
HIAA or kynurenine. Taking account of age and BMI, the
ratio of kynurenate to 3HK, was lower in children with
ADHD than the comparison groups which showed
slightly increased levels of 3HK.
There were no group differences in S100B levels, but
reductions in ADHD children reflected those with inter-
nalizing rather than conduct problems [11]. Except for
IL-1β and TNF-α the normalised cytokine values (figure
1) tended to be higher in the ADHD than in the control
group. All values in the ADHDmed group returned to
more normal levels.
(2) Relations of biochemical measures to group features, 
symptoms and attention
Group features (relations to tryptophan metabolism and the 
cytokines)
Across all children tryptophan levels increased with BMI
and age (R2 0.14, F(1,54) = 8.69: β +0.37, p = 0.005): this
was evident in both the ADHD and ADHDmed groups
(R2 0.22/0.60, F(1,19) = 5.33/8.16: β + 0.47/+0.96, p =
0.03/0.002, respectively). 3HK levels also tended to
increase in controls (R2 0.20, F(1,19) = 4.69, β +0.45, p =
0.04). IQ was unrelated, but low SES was predicted by
lower tryptophan and increasing kynurenate levels (R2
0.15, F(2,53) = 4.70: β + 0.33/-0.34, p = 0.018/0.015,
respectively). This was supported by modest associations
with increased tryptophan breakdown and lower neuro-
protection ratio-B (β -0.3/-0.28, p = 0.02/0.03). Lastly,
across all children (and within each group), those with an
experience of allergy tended to be predicted by low levels
of 5-HIAA (R2 0.07, F(1,54) = 3.93: β -0.26, p = 0.05).
Table 2: Conners Parent and Teacher Rating Scale Assessments (CPRS/CTRS) of ADHD Symptoms (means and standard 
errors)
ADHD (N = 20) sem CON (N = 21) sem ADHDmed (N = 14) sem
CPRS
Opposition 71.4 2.1 51.7** 2.1 71.5 2.6
Anxiety 56.3 2.3 51.1# 2.3 58.2 2.9
DSM-IA 72.1 2.2 47.8** 2.2 69.3 2.8
DSM-HI 78.4 1.9 48.1** 1.8 72.8 2.3
DSM-sum 76.4 1.8 48.0** 1.7 72.6 2.2
CTRS
opposition 63.3 2.5 50.8 2.4 56.0 3.1
Anxiety 60.3 2.8 54.8 2.6 62.3 3.4
DSM-IA 65.8 2.5 48.6* 2.3 59.9 3.0
DSM-HI 67.7 2.5 48.4* 2.3 51.5 3.0
DSM-sum 68.1 2.3 48.5* 2.2 57.0 2.9
For all subscales (except anxiety) the ADHD groups scored higher than children without a diagnosis (independent of 4 covariates): IA, 
inattention; HI, hyperactivity-impulsivity: # F(2,49) = 2.7 p = 0.077, η2 = 0.099; * F(2,49) = 7-11, p < 0.002 η2 = 0.23-0.32; ** F(2,49) = 34-74, p < 
0.000, η2 = 0.49-0.69;Oades et al. Behavioral and Brain Functions 2010, 6:32
http://www.behavioralandbrainfunctions.com/content/6/1/32
Page 7 of 19
Table 3: Continuous performance task measures (CPT/Qb) of motor activity, response speed/variability and accuracy/
errors
CPT/Qb measure Group N Mean SD df 2,50
Duration active ADHD 21 43.4 23.7
(% > 1 cm/sec) CON 21 15.6 11 F 5.6, p = 0.006, η2 = 0.18
ADHDmed 13 23.52 21.9
Microevents ADHD 21 10167 5624
(N > 1 mm) CON 21 4390 1962 F 5.0, p = 0.01, η2 = 0.17
ADHDmed 13 55311 3626
RT (ms) ADHD 21 581 85
CON 21 444 92 F 4.1, p = 0.02, η2 = 0.14
ADHDmed 13 533 141
CV ADHD 21 44.1 15.4
100 × RT-SD/RT CON 21 29.2 5.1 F 5.2, p = 0.009, η2 = 0.17
ADHDmed 13 333 7.7
Errors
Omissions ADHD 21 20.4 17
CON 21 2 3 F 5.6, p = .006, η2 = 0.18
A D H D m e d 1 31 9 . 42 4 . 2
Commissions ADHD 21 17.3 9.1
CON 21 9.7 7.4 NS
ADHDmed 13 6.44 9.7
ADHD vs. ADHDmed: 1. p = 0.006, 2. p = 0.014, 3. p = 0.013, 4. p = 0.002Oades et al. Behavioral and Brain Functions 2010, 6:32
http://www.behavioralandbrainfunctions.com/content/6/1/32
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Group features were only marginally predicted by the
levels of a few proinflammatory cytokines. Across all sub-
jects increasing TNF-α and decreasing IFN-γ levels
tended to predict increasing age (R2 0.084, F(2,53) = 0.09:
β +0.28/-0.31, p = 0.077/0.049, respectively). BMI also
tended to be predicted by increasing TNF-α and IL-6 lev-
els (β +0.32/+0.45, p = 0.03/0.001, respectively).
Across subjects allergic experience tended to relate to
decreasing proinflammatory TNF-α but increasing anti-
inflammatory IL-10 levels (R2 0.16, F(2,53) = 5.0, p = 0.01:
β -0.27/ + 0.31, p = 0.039/0.017, respectively). In the
ADHD group, in addition to the TNF-α decrease, (β -
0.63, p = 0.03) increasing antiinflammatory IL-13 levels
predicted response (β +0.56, p = 0.01). In contrast, for the
controls alone the increase in IL-10 was masked by
decreases of IL-13 in the prediction of allergy severity (R2
0.42, F(2,18) = 6.6, p = 0.007: β + 0.33/-0.13, p = 0.08/0.01,
respectively).
Summary
Tryptophan levels increased with age and BMI, but lower
SES status facilitated metabolism in the kynurenine path-
way. Some proinflammatory cytokine levels decreased
(IFN-γ) or increased with BMI (TNF-α, IL-6). Indepen-
dent of diagnosis, children with allergies tended to show
lower levels of 5-HT metabolism. Most children with
experience of allergy showed decreases of the proinflam-
matory TNF-α. However, in contrast to the controls who
showed decreases of the anti-inflammatory IL-13, the
ADHD group showed increased IL-13 levels.
Symptom ratings: relations of tryptophan metabolism
In general, symptoms were not associated clearly with
tryptophan metabolism. Partial correlations accounting
for age, BMI and SES suggested that inattentive symp-
toms were related to tryptophan levels across all children
(r = +0.32, p = 0.026). Alone for controls anxiety related
to 5-HIAA levels (r = 0.52, p = 0.038) and inattentive rat-
ings with 3HK (r = +0.49, p = 0.037). Only the latter result
(3HK) approached the threshold for significance in the
regression (R2 0.19, F(1,19) = 4.5: β +0.44, p = 0.048).
Symptom ratings: relations of cytokine measures
Overall, considering total symptom ratings in the ADHD
group the best predictors were increasing levels of IL-13
and IL-16 along with decreasing levels of S100B (R2 0.57,
F(4,16) = 5.21, p = 0.007: β +0.59, +0.51, -0.54, p = 0.024,
Figure 2 shows a comparison for the 4 groups of subjects of the levels of tryptophan, its metabolites and the indices for tryptophan avail-
ability, breakdown and neuroprotection (A and B). Tryptophan levels and availability were higher in both ADHD groups (p < 0.02). Descriptively 
higher levels of 3HK in the controls (p < 0.08) related closely to Kynurenine levels (r = + 0.85, p < 0.000), but a correlation was absent in the ADHD 
group (p = 0.35).Oades et al. Behavioral and Brain Functions 2010, 6:32
http://www.behavioralandbrainfunctions.com/content/6/1/32
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0.019, 0.013, respectively) with a minor contribution from
TNF-α.
Partial correlations accounting for age, BMI and SES
pointed to associations for pro-inflammatory cytokines
with two symptom groupings, namely the oppositional
and hyperactive-impulsive ratings. In the ADHD group
decreasing IL-2 (r -0.64, p = 0.026) and TNF-α (r -0.62, p
= 0.018: figure 3) correlated with increased ratings of
opposition. Regression confirmed the IL-2 result (R2 0.41,
F(2,18) = 6.2, p = 0.009: β -0.55, p = 0.007: figure 4) and
implied a modest predictive role for increasing levels of
S100B (β +0.37 p = 0.057). Of interest is that in the con-
trols another proinflammatory cytokine (IL-6) correlated
with oppositional ratings (r +0.48, p = 0.05): the predic-
tive role was confirmed in the regression (R2 0.30, F(1,19)
= 7.99, p = 0.01: β +0.54, p = 0.01).
The association of hyperactive-impulsive ratings in the
ADHD group with IL-16 (r +0.66, p = 0.015) was con-
firmed by the regression (R2 0.52, F(2,18) = 9.82, p =
0.001: β +0.80, p = 0.000) with modest support from
decreasing levels of S100B (β -0.42, p = 0.035). Anxiety
ratings were without relationships to the cytokines. But,
intriguingly ratings of inattention in the ADHD group
tended to relate positively to levels of the antiinflamma-
tory IL-13, yet negatively to IL-13 in the controls (R2 0.33/
0.45, F(2/3, 18/17) = 4.5/4.6, p = 0.026/0.015: β +0.44/-
0.67, p = 0.03/0.007, respectively: figure 5). The ADHD
result was modestly supported by increasing IL-6 levels
(β +0.38) and the control result by increasing S100B (β +
0.64).
Summary
There were modest associations of tryptophan levels and
its metabolism to the potentially toxic 3HK with inatten-
tion, and 5-HT metabolism to anxiety. Proinflammatory
cytokines were associated with oppositional symptoms:
decreases of IL-2 in the ADHD group contrasted with
increases of IL-6 in the controls. In general, ADHD
symptoms were associated with increases of the antiin-
Figure 3 For children with ADHD, ratings of oppositional behaviour vs. levels of TNF-α (linear regression).Oades et al. Behavioral and Brain Functions 2010, 6:32
http://www.behavioralandbrainfunctions.com/content/6/1/32
Page 10 of 19
flammatory IL-13 (inattention), increases of IL-16
(hyperactive-impulsive symptoms) and with decreases of
S100B (total symptoms).
CPT performance: relations of tryptophan metabolism
Across all subjects motor activity (duration, microevents)
showed a very modest tendency to increase with lower
levels of 3HK (R2 0.07, F(1,54) = 4.0/3.4: β-0.26/-0.24, p =
0.05/0.07, respectively), but this was not evident in the
partial correlations and single group analyses.
In control children faster RTs were associated with
increasing kynurenine levels (R2 0.32, F(1,19) = 9.13: β -
0.57, p = 0.007: figure 6). This confirmed the partial cor-
relation (r = -0.52, p = 0.026). Unexpectedly, the opposite
relationship appeared in the ADHDmed group (r = +
0.93, p = 0.000: R2 0.48, F(1,12) = 10.93: β +.69, p = 0.006)
with no association evident in the non-medicated cases.
Across all subjects, there was a partial correlation for the
coefficient of RT variance with tryptophan levels (r+0.30,
p = 0.035), yet a predictive role for tryptophan was not
confirmed in the regression. Interestingly, the decrease of
tryptophan (and variability) in controls (vs. the ADHD
group, figure 2) tended to be reflected by increases of 5-
HIAA (r = -0.45, R2 0.17, F(1,19) = 3.95: β -0.42, p = 0.06).
But, no associations were evident in the ADHD groups.
The interpretation of the RT associations in terms of 5-
HT metabolism is supported by the partial correlations of
the turnover indices. While tryptophan availability was
positively related to RT (r+0.36, p = 0.012), the break-
down to kynurenine was negatively associated (r-0.31, p =
0.03).
The error analysis suggested that omissions were posi-
tively associated with tryptophan levels across subjects (r
= +0.38 p = 0.006: R2 0.14, F(1,54) = 9.03: β +0.38, p =
0.004). This positive association between tryptophan lev-
els and omission errors was evident as a trend in the
ADHDmed group where the relationship to commission
errors was negative (R2 0.35/0.54, F(1,12)/(2,11) = 6.37/
6.42: β +0.59/-0.92, p = 0.027/0.004, respectively). This
Figure 4 For children with ADHD, ratings of oppositional behaviour vs. levels of IL-2 (linear regression).Oades et al. Behavioral and Brain Functions 2010, 6:32
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negative trend with commission errors is upheld by their
association with the tryptophan breakdown index (R2
0.49, F(1,12) = 11.8: β +0.70, p = 0.005).
CPT performance: relations of cytokine measures
Considering motor activity across all subjects, the partial
correlations pointed to a positive association of the dura-
tion measure with IL-16 levels (r+0.30, p = 0.038). This
was confirmed by the regression (R2 0.08, F(1,54) = 4.56: β
+0.28, p = 0.037). The motor associations appeared to be
driven by IL-16 in the ADHD group for both duration
and microevent measures (R2 0.55/0.47, F(3,17) = 6.9/5.0,
p = 0.003/0.01: β +0.55/+0.47, p = 0.007/0.028, respec-
tively). [The other degrees of freedom here refer to minor
contributions from decreases of the pro-inflammatory
IL-6 and TNF-α.] In contrast, the effect of medication
introduced a potential modest antiinflammatory influ-
ence (e.g. IL-10 with microevents, R2 0.35, F(1,12) = 6.3: β
+0.59, p = 0.027).
Several analyses indicated minor negative associations
of RT with cytokines (e.g. IL-2, S100B) but only the effect
of medication showed that decreasing RTs related to
increasing levels of IL-2 (ADHDmed: β -0.73, p = 0.003:
figure 7). This contrasts with RT variability, where across
subjects the coefficient of variance was influenced in
opposite ways by TNF-α and IFN-γ (R2 0.18, F(2,53) = 6.1,
p = 0.004: β -0.46/+0.04, p = 0.002/0.007, respectively: fig-
ure 8). While these two relationships were not driven by
processes related to diagnosis, the association with TNF-
α was most marked in the medicated ADHD group (β -
0.70, p = 0.007).
In the error analyses errors of commission were pre-
dicted by levels of IL-16 (r+0.42, p = 0.003: R2  0.17,
F(1,54) = 10.75: β +0.41, p = 0.002: figure 9). But, as with
Figure 5 For children with ADHD, ratings of inattention vs. levels of IL-13 (linear regression).Oades et al. Behavioral and Brain Functions 2010, 6:32
http://www.behavioralandbrainfunctions.com/content/6/1/32
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variability (above) this was most apparent in the ADH-
Dmed group (β +0.75, p = 0.000). In this group alone,
again as with variability, decreases of proinflammatory
TNF-α (β-0.36, p = 0.016) and IL-6 (β-0.39, p = 0.032)
also tended to predict errors of commission. For omission
errors only the negative associations of IL-13 (ADHD: β-
0.47, p = 0.03)) and IL-16 (ADHDmed: β-0.63, p = 0.004)
were of note.
Summary
Measures of motor activity were not related to trypto-
phan metabolism but were positively predicted by IL-16
levels. In contrast, shorter RTs were associated with
increasing kynurenine levels in controls, but by decreas-
ing levels in the ADHDmed group. Here, the cytokines
were without any major influence. Interestingly,
decreased RT variability in controls was reflected by
modest increases of catabolism to 5-HIAA. With regard
to the cytokines, across subjects, levels of variability
reflected the opposing influences of TNF-α and IFN-γ. In
the error analysis, while the build up of tryptophan pre-
dicted omission errors, its breakdown predicted errors of
commission. But only the errors of commission were pre-
dicted by IL-16 levels. Medication may moderate interac-
tions of pro-and antiinflammatory cytokines in motor
activity (IL-2/RT, IL-10/microevents) and the influences
of proinflammatory TNF-α, IL-6 (variable RT) and IL-16
(impulsivity).
Discussion
Over 20 years ago Kim and Choi [34] demonstrated that
the breakdown of tryptophan and kynurenine can pro-
duce toxic metabolites (3HK and quinolinate) in neocor-
tical tissue, but an alternative pathway produces
kynurenate that can be protective. Kynurenine metabo-
lism in the brain occurs largely in the glia that envelop
glutamatergic synapses [12]. Among the numerous
responses of the glia to excitotoxicity are alterations in
the proinflammatory cytokines, such as TNF-α and IFN-
Figure 6 For healthy control children, reaction time (RT) on the CPT task vs. levels of kynurenine (linear regression).Oades et al. Behavioral and Brain Functions 2010, 6:32
http://www.behavioralandbrainfunctions.com/content/6/1/32
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γ [35], where the balance with antiinflammatory cytok-
ines influences tryptophan metabolism [13]. Recently
there have been numerous reports of associations of
kynurenine metabolites and cytokines with brain damage
and psychiatric disorders [8,36-40]. While we only found
modest changes of selected markers of these cytokines
and metabolites in our pilot study of ADHD [11], we
hypothesized here that key symptoms and poor atten-
tional function would reflect alterations of the activity of
these markers. Features of the kynurenine metabolic
pathway and neuroinflammatory activity of cytokines
have not been explored before in the context of ADHD.
We report a preliminary exploration of whether prod-
ucts of tryptophan metabolism and the cytokines that
modulate this metabolism predict some of these symp-
toms, and their laboratory measures in children with a
strict diagnosis of ADHD (combined type) contrasted
with those developing normally. The study is predicated
on increasing evidence that alterations in these two bio-
chemical domains are reflected in both the features of
ADHD [21,41] and animal models of these functions
[42,43].
Those with the diagnosis of ADHD had clearly more
symptoms of inattention, hyperactivity-impulsivity and
opposition than those without the diagnosis. On a test of
sustained attention the children with ADHD showed
more motor activity, errors of omission, a slower RT and
more RT variability. Most cytokine levels were modestly
increased in children with ADHD (not S100B and IL-1β)
and all tended to normalize on psychostimulant medica-
tion. While tryptophan availability was slightly increased
in the ADHD group, 3HK levels tended to be lower than
in the controls [11].
The cytokines and associations with symptoms
The DSM ratings of total symptom severity in the ADHD
group were predicted by increasing levels of IL-16, and
the anti-inflammatory IL-13, but by decreasing levels of
Figure 7 For children with ADHD on medication the reaction time vs. levels of IL-2 (linear regression).Oades et al. Behavioral and Brain Functions 2010, 6:32
http://www.behavioralandbrainfunctions.com/content/6/1/32
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S100B. The anti-inflammatory relationship was modestly
evident for inattentive symptoms in the ADHD group,
and arguably effective in countering dysfunction in that
higher levels of IL-13 in the controls were related to fewer
symptoms of inattention. The role of IL-16 can be pro-or
anti-inflammatory in different situations [44,45]. Here, in
the ADHD group, IL-16 levels additionally predicted
hyperactive-impulsive symptoms that were also modestly
associated with decreased S100B. The IL-16 relationship
with hyperactive symptoms might not be expected in so
far as 2 genetic polymorphisms have been associated with
the inattentive type of ADHD [46]. However, the differ-
ence may reflect other features of the two populations
influencing the neuroinflammatory role of IL-16, such as
allergy (see below). The association of symptom severity
with decreasing S100B levels is consistent with our pre-
diction of inefficient glial function in ADHD [11] rather
than an overproduction resulting from apoptosis and
brain damage reported for other major psychiatric disor-
ders [10,47,48].
Only proinflammatory cytokine activity related to
oppositional symptom ratings. Decreasing levels of IL-2,
and to a minor extent TNF-a, were associated with
increasing signs of opposition. We suggest the negative
direction of association mirrors consistently the frequent
reports of increased IL-2 activity in disorders such as
schizophrenia and Parkinsonism with a very different
clinical profile [40,49,50]. On the other hand we note a
relationship between increasing IL-6 and oppositional
behaviour in the control group. We tentatively suggest
that, as IL-6 levels increased with BMI and the controls
were marginally older than the patients, such an increase
reflects the normal parallel development of boisterous
behaviour often associated with adolescence onset. This
interpretation is also consistent with the well-studied
associations of IL-6 levels with physical and psychological
stress [51].
Figure 8 For all subjects, the coefficient of variance (CV) vs. levels of TNF-α (linear regression).Oades et al. Behavioral and Brain Functions 2010, 6:32
http://www.behavioralandbrainfunctions.com/content/6/1/32
Page 15 of 19
Sensitivity to allergy reflected opposing trends for pro-
and antiinflammatory cytokines. Children sensitive to
allergy showed 15% more IL-16, 32% more IL-13 and sim-
ilar levels of IL-10 [11]. But for the ADHD children who
experienced allergic responses, these responses tended to
be predicted by decreasing levels of the proinflammatory
TNF-α and increases of the antiinflammatory IL-13. For
controls the trend went in the opposite direction for IL-
13, but this was balanced by modest increases of another
antiinflammatory cytokine, IL-10. The difference
between groups in the proinflammatory response is
quantitative, but that for the antiinflammatory response
is qualitative. This physiological response may underlie a
subgroup of ADHD children with high allergic responsiv-
ity and for whom ADHD symptoms are alleviated by
removal of the allergens from the diet [52-54]. Further,
IL-10 secretion is facilitated by physical or psychological
stress [55] and could be responsible for the decreases of
tryptophan metabolism [56] discussed below.
The cytokines and associations with CPT performance
During the CPT both the duration of major movements
and the quantity of small fidgety activity (microevents)
were directly measured. Increasing IL-16 levels not only
predicted hyperactive symptoms (above) but clearly pre-
dicted quantitative measures of motor activity, especially
(but not only) in ADHD children. The associations
extended to error omission and commission in the medi-
cated children that may reflect motor as well as cognitive
control. The associations of IL-16 with motor activity and
allergy in this study clearly add to the concept of this
being a pleiotropic cytokine, for which not all the roles
have yet been elaborated.
Accuracy in terms of the errors made is more usually
thought of as a cognitive than a motoric feature. Our data
suggest that decreasing levels of the anti-inflammatory
IL-13 may not only relate to inattentive symptoms
(above), but specifically to increases of errors of omission.
But, both this association and the tendency for errors of
Figure 9 For all subjects, commission errors on the continuous performance test vs. levels of IL-16 (linear regression).Oades et al. Behavioral and Brain Functions 2010, 6:32
http://www.behavioralandbrainfunctions.com/content/6/1/32
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commission in medicated children to be reduced as pro-
inflammatory TNF-α and IL-6 levels increased were
modest trends. This should be examined closely in future
studies. Nonetheless the increase of IL-2 with decreased
RT in the ADHDmed group supports the proinflamma-
tory effect on attention-related function.
Associations of the coefficient of variance of the RT is
of especial interest, first as variability is the core feature of
the hypothesis of glial impairment in ADHD [5], and sec-
ondly as it has been proposed as an endophenotype for
ADHD (introduction). Here, across all subjects, increas-
ing RT variability was related to decreasing levels of TNF-
α and with increasing levels of IFN-γ.
Numerous studies confirm the involvement of proin-
flammatory cytokines in cognitive performance both in
animal models and in the treatment of cancer patients.
For example IL-2 treatment can interfere with long term
potentiation in the hippocampal slice [57] and the forma-
t i o n  o f  w o r k i n g  m e m o r y  i n  p a t i e n t s  [ 5 8 ] .  T r e a t i n g
rodents with IL-6 can impair measures of memory
[59,60], yet in knockout mice recall can be facilitated
[61,62]: the relationship of IL-6 to cognitive function may
be linear or U-shaped [63]. However, IL-6 expression
depends on the nature of the allele carried (CC/GC geno-
type) and this variable has too rarely been considered
[64,65]: the C allele may dominate in ADHD while the
protective G allele may predominate in typically develop-
ing children [66]. The characteristics of TNF-α and IFN-γ
have much in common with other proinflammatory
interleukins. Too much [67] or too little TNF-α [68] can
impair cognitive function, but moderate levels are essen-
tial [69]. Variation of these levels can influence the turn-
o v e r  o f  e a c h  o f  t h e  m o n o a m i n e s  [ 7 0 ] .  T h u s  i t  i s  n o
surprise that TNF-α levels relate to accuracy and the vari-
ability of response in ADHD. However, the relationship of
the effects with those of IFN-γ require closer study, as the
physiological response to each varies with the measure
and over time [70].
Tryptophan metabolism and associations with symptoms 
and CPT performance
Even after controlling for age, BMI and SES there were
tendencies across subjects for a build-up of tryptophan
(and its increased availability) to be associated with
symptoms of inattention, RT and its variability as well as
increases of errors of omission. In contrast decreased
tryptophan levels (more breakdown) related to errors of
commission. However, tryptophan metabolism was not
related to motor activity. This was unexpected as the
motor regions of the brain receive a dense 5-HT innerva-
tion [71].
For controls, slower RTs but for the ADHDmed group
faster RTs were clearly associated with lower kynurenine
levels. There was an indication that low levels of kynure-
nine for controls was reflected by the trend for reduced
variability and an associated increase of metabolism in
the 5-HT pathway. For medicated children the implica-
tion is of further glial metabolism in the kynurenine path-
way that is facilitated by psychostimulant treatment [72].
Other trend relationships (e.g. 3HK with inattention, 5-
HIAA with anxiety) were equivocal. The lack of antici-
pated changes of 5-HT metabolism related to antisocial/
oppositional behaviour [73,74] may simply reflect the
extent of 5-HT metabolism from peripheral sources.
The absence of clear associations for tryptophan
metabolism with symptoms or attention related perfor-
mance in ADHD is itself of interest. An overexpression of
indoleamine 2, 3 dioxygenase facilitates degradation to
kynurenine (and its potentially toxic metabolites) and
reduced 5-HT metabolism [75]. Such activity is promoted
by proinflammatory cytokines [76]. This scenario fits evi-
dence for the development of psychotic symptoms [38]
and major depression [13]. But, our results tend to sup-
port the opposite effect in ADHD with increases of tryp-
tophan availability relating to inattention and variable
responses. Indeed, here there was even modest support
for previous evidence for an involvement of 5-HT metab-
olism [77].
We had anticipated that the cytokine balance would
favour kynurenine breakdown to either kynurenate or
3HK. On the basis of their glutamatergic antagonist and
agonist activity these metabolites (and the 3HK metabo-
lite quinolinate) have been ascribed a neuroprotective
and toxic role, respectively [78]. But in fact our typically
developing children rather than the ADHD group showed
descriptively higher levels of kynurenate and 3HK. Yet,
these measures did not predict symptoms or CPT perfor-
mance. We speculate that the ADHD children in fact
exhibit a relative lack of some of the other characteristics
of these metabolites. For example, kynurenate also has α7
cholinergic antagonist properties [79] and higher levels
antagonize rather than facilitate AMP A receptor trans-
mission [80]. 3HK has antioxidant capability ([81]) as well
as the toxic potential to assist in developmental pruning
[16]. Indeed, it is unclear as yet whether energy metabo-
lism in developing children would be impaired by the
NMDA agonism of quinolinate [82] or facilitated through
further metabolism to NAD(+) [83].
Limitations
Our conclusions are severely curtailed by not having
measured other metabolites (picolinic and, quinolinic
acid, NAD(+)), enzyme activity or the expression of
genetic variants for these. Also in a pilot study the robust-
ness of the data is naturally compromised by the small
number of children that could be recruited and per-
suaded to offer a blood sample. However, this exploration
with 56 children indicates a number of lines of inquiryOades et al. Behavioral and Brain Functions 2010, 6:32
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that are not worth pursuing and others that might merit
further study. Indeed, although the number of variables
examined raises questions about the prevalence of false
positive results, the statistical procedure included confir-
matory tests and false discovery assessment to limit this.
Cytokine measures, renowned for their variability, were
relatively consistent with remarkably few outliers. Future
work should seek replication with a longitudinal design to
demonstrate consistency of the data in a larger sample.
Such a design should account for developmental age,
match for gender, and control for medication yet recruit
cases with a range of comorbid attributes to clarify their
contribution to the diagnostic condition.
Conclusions
We hypothesised that even if there are no major dichoto-
mies for this selection of metabolites and cytokines
between the groups studied, there would be some associ-
ations between symptom dimensions or attentional fea-
tures and the activity of individual markers. In this
exploration we have been able to point out some such
associations that bear further study. Some regressions
predicted 10 to 40% of the variance of the variable in
question.
While in most cases the elements of the kynurenine
pathway analysed did not show strong associations with
behaviour, we are aware that those metabolites determin-
ing toxicity or energy supply were missing (e.g. quinolinic
acid, NAD(+)). Only such a determination can link
unequivocally putative maturation-related pruning (3HK
levels) or glial energy supply [5] to metabolism. However,
independent of kynurenine metabolism, among the
cytokines there appears to be a conceptual division
between the activity of antiinflammatory members with
motor-control related features (symptoms, microevents)
and pro-inflammatory members with cognitive-control
features (opposition, variability). In several instances the
associations extended across all subjects implying their
quantitative trait nature. We recommend replications to
include the pro-inflammatory IL-1β and antiinflamma-
tory IL-4 and comparisons to examine stability of these
associations before and after adolescence.
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